Natural Product (NP) Details
| General Information of the NP (ID: NP6205) | |||||
|---|---|---|---|---|---|
| Name |
Asiatic acid
|
||||
| Synonyms |
Asiatic acid; 464-92-6; Dammarolic acid; UNII-9PA5A687X5; MFCD00238541; NSC 166063; Asiantic acid; CHEBI:2873; CHEMBL404313; 9PA5A687X5; 2,3,23-trihydroxyurs-12-en-28-oic acid; Asiatic-acid; HSDB 7662; NSC-166063; Asiatic acid, 97%; SCHEMBL3285999; 2alpha,23-Dihydroxyursolic acid; Asiatic acid, analytical standard; DTXSID901019207; HY-N0194; ZINC8221271; BDBM50241487; AKOS007930256; Urs-12-en-28-oic acid, 2,3,23-trihydroxy-, (2.alpha.,3.beta.,4.alpha.)-; CCG-208549; DB14054; MCULE-1974040943; NCGC00346584-02; CS-0007893; N1356; V1794; C08617; 464A926; Q-100489; Asiatic acid, >=98% (HPLC), from Centella asiatica; BRD-K35079116-001-03-3; Q15478109; (2alpha,3beta)-2,3,23-trihydroxyurs-12-en-28-oic acid; (4alpha)-2alpha,3beta,23-trihydroxy-urs-12-en-28-oic acid; (2alpha,3beta,5beta,20beta)-2,3,23-trihydroxyurs-12-en-28-oic acid; (4I+/-)-a?I+/-,a?I(2),a?3-atrihydroxy-aurs-a?2-aen-a?8-aoic acid; Urs-12-en-28-oic acid, 2,3,23-trihydroxy-, (2alpha,3beta,4alpha)-; Urs-12en-28-oic acid, 2,3,23-trihydroxy-, (2alpha, 3beta, 4alpha)-; (1S,2R,4aS,6aS,6bR,8aR,9R,10R,11R,12aR,12bR,14bS)-10,11-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid; 0AS
Click to Show/Hide
|
||||
| Species Origin | Centella asiatica ... | Click to Show/Hide | |||
| Centella asiatica | |||||
| Disease | Breast cancer [ICD-11: 2C60] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C30H48O5
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)CO)O)O)C)C)C2C1C)C)C(=O)O
|
||||
| InChI |
1S/C30H48O5/c1-17-9-12-30(25(34)35)14-13-28(5)19(23(30)18(17)2)7-8-22-26(3)15-20(32)24(33)27(4,16-31)21(26)10-11-29(22,28)6/h7,17-18,20-24,31-33H,8-16H2,1-6H3,(H,34,35)/t17-,18+,20-,21-,22-,23+,24+,26+,27+,28-,29-,30+/m1/s1
|
||||
| InChIKey |
JXSVIVRDWWRQRT-UYDOISQJSA-N
|
||||
| CAS Number |
CAS 464-92-6
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | SMAD7 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Twenty-four C57BL/6 male mice were used in this study | |||||
| Experimental
Result(s) |
Asiatic acid protects against cisplatin-induced AKI via anti-apoptosis and anti-inflammation. | |||||
| Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | H9c2(2-1) | CVCL_0286 | Healthy | Rattus norvegicus | ||
| In-vivo Model | Male C57BL/6 mice were used in this study. | |||||
| Experimental
Result(s) |
Asiatic acid could attenuate DOX-induced myocardial oxidative stress and apoptosis via activation of the AKT signaling pathway. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Myophosphorylase (PYGM) | Molecule Info | [4] | |
